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Abstract: Formation of advanced glycation end products (AGEs) by nonenzymatic glycation
of proteins is a major contributory factor to the pathophysiology of diabetic conditions including
senile dementia and atherosclerosis. This study describes the inhibitory effect of gold nanoparticles (GNPs) on the D-ribose glycation of bovine serum albumin (BSA). A combination of
analytical methods including ultraviolet–visible spectrometry, high performance liquid chromatography, circular dichroism, and matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry were used to determine the extent of BSA glycation in the
presence of citrate reduced spherical GNPs of various sizes and concentrations. GNPs of particle
diameters ranging from 2 nm to 20 nm inhibited BSA’s AGE formation. The extent of inhibition correlated with the total surface area of the nanoparticles. GNPs of highest total surface
area yielded the most inhibition whereas those with the lowest total surface area inhibited the
formation of AGEs the least. Additionally, when GNPs’ total surface areas were set the same,
their antiglycation activities were similar. This inhibitory effect of GNPs on BSA’s glycation by
D-ribose suggests that colloidal particles may have a therapeutic application for the treatment
of diabetes and conditions that promote hyperglycemia.
Keywords: gold nanoparticles, glycation, AGEs, GNPs, BSA
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Albumin, the most abundant plasma protein, is a multifunctional biomolecule involved
in a wide variety of physiological activities.1,2 Glycation of albumin and other proteins
can generate advanced glycation end products (AGEs) leading to several chronic complications of diabetes including atherosclerosis, renal failure, and cataract formation.3–5
Current efforts to reduce the formation of AGEs have focused on a number of synthetic
drugs such as aminoguanidine and metformin.6–8 Although some of these compounds
have shown promising inhibitory effects on AGE formation, they have been also found
to cause side effects.7 Recently, studies have reported that gold nanoparticles (GNPs),
a substance widely applied in the field of nanomedicine, can act as an antiglycation
agent reducing the formation of AGEs.9–11 With this potential, GNPs may provide a
safer approach for the treatment of AGE-related disease.
Under normal conditions, albumin has a half-life of about 21 days and a plasmatic
concentration ranging from 35 to 54 mg/mL.12 Being highly exposed to different
biomolecules in the blood, albumin is susceptible to enzymatic and nonenzymatic
changes.1,2,13 Of the nonenzymatic changes contributing to modifications in albumin’s
structure and function, the glycation of the molecule by reducing sugars has received
considerable attention.13–15
Glycation of albumin initiates with a condensation reaction between the amino
groups on the protein and the carbonyl group of a reducing sugar, yielding unstable
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Schiff base structures. 14 These intermediary unstable
compounds can rearrange to form more stable ketoamine
structures that, over time, promote the production of a heterogeneous group of molecules commonly referred to as
AGEs.16–19 The formation of AGEs is not limited to albumin
or other proteins. In fact, many amino containing molecules
such as lipids, deoxyribonucleic acid (DNA), and ribonucleic
acid (RNA) have been reported to be glycated both in vitro
and in vivo.20–22 Under conditions promoting hyperglycemia, AGEs can accumulate in the body and contribute to
many of the chronic complications of diabetes and classical
galactosemia.3–5,23,24
GNPs, also referred to as colloidal gold particles, are
a suspension of gold beads that in solution can range in
size from one to several hundred nanometers.25 Because of
their unique optical properties, variable surface-to-volume
ratios, and their ease of production, GNPs have been used
in a wide range of applications. In the medicine field, for
instance, GNPs have been used for diagnostic and imaging
purposes,26,27 whereas in the pharmaceutical industry their
applications have extended to such areas as drug delivery
and medicinal chemistry.28–30
Studies in our laboratory9 and others10,11 have recently
demonstrated that GNPs can reduce the formation of AGEs,
with these reductions occurring under physiological temperature and pH conditions. Considering that GNPs may provide
an alternative approach to reducing AGEs and AGE-related
diseases (ie, besides the use of synthetic drugs), in this study,
we focused on two objectives: 1) the inhibitory effects of
citrate coated spherical GNPs on the glycation of albumin
by D-ribose, and 2) the effects of GNP size, concentration,
and total surface area on the extent modification of albumin
by D-ribose.
This report describes for the first time 1) the inhibition
of albumin glycation in the presence of GNPs by D-ribose,
and 2) a correlation between GNP’s total surface area and
the formation of AGE products.

Materials and methods
Reagents
Bovine serum albumin (BSA) and analytical grade D-ribose
were obtained from Sigma-Aldrich Chemical Co. (St. Louis,
MO, USA). Citrate reduced spherical GNPs with variable
diameters (2 nm, 5 nm, 20 nm, 50 nm, 100 nm, and 200 nm)
were purchased form Ted Pella, Inc. (Redding, CA, USA).
The size, concentration, and characterization of the colloidal suspension were determined by the manufacturer
of the GNPs, BBI Solutions (Cardiff, UK), according to
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standard protocols (http://www.tedpella.com/gold_html/
goldsols.htm) using ultraviolet–visible (UV–Vis) spectroscopy and transmission electron microscopy. Disposable
UV-transparent cuvettes (12.5 mm×12.5 mm×36 mm) and
high performance liquid chromatography (HPLC) analytical
grade solvents were procured from Thermo Fisher Scientific
(Rockford, IL, USA). ZipTip pipette tips with C4 resin and
0.22 µm filter unit were obtained from EMD Millipore Co.
(Billerica, MA, USA).

Preparation of reaction incubation mixtures
To test the effects of GNPs on BSA’s glycation by D-Ribose,
two different groups of reaction mixtures hereinafter referred
to as A and B were prepared. Incubation mixtures A had GNP
suspensions of variable surface area and those in B had colloidal suspensions whose surface areas were held constant.
Unless otherwise indicated, all of the aforementioned mixtures were prepared in 0.1 M phosphate buffer, pH 7.2.
Incubation mixtures A contained GNP suspensions of
various concentrations and sizes (2 nm, 5 nm, and 20 nm), 35
mg/mL albumin set at the physiological levels of the protein
in blood, and 20 mM D-ribose. The concentration of D-ribose
was set at 20 mM to mimic D-glucose concentrations sometimes seen in the blood of patients with diabetes.1 Incubation
mixtures B were prepared in a similar manner as incubation
mixtures A but with GNPs’ total surface areas adjusting to
the same value in each colloidal suspension.
The shaded area in Table 1 summarizes the technical details of all GNP suspensions in incubation mixtures
A and B based on the data provided by the manufacturer
of the GNPs, BBI Solutions (Cardiff, UK). The total surface areas were determined by taking into account both the
size of the particles and their concentrations. Total surface
areas were calculated by the formula 4πr2×C where r and C,
respectively, represent the radius of the nanoparticles and
their particle concentrations.
The choice of particle size in this study was based on the
observation that precipitation of GNPs routinely occurred
when the glycation of BSA was performed in the presence of
colloidal suspensions with diameters exceeding 20 nm. Smaller
diameter particles of sizes 2 nm, 5 nm, and 20 nm exhibited
no such effects and were thus included in this study to further
evaluate their inhibitory effect on the formation of AGEs.

Preparation of blank and control solutions
Blank solutions included BSA alone (35 mg/mL), D-ribose
alone (20 mM), or BSA (35 mg/mL) with the different size
GNPs in 0.1 M phosphate buffer, pH 7.2. Control solutions

International Journal of Nanomedicine 2014:9

Dovepress

Anti-glycation effect of gold nanoparticles

Table 1 Constituents of colloidal suspension mixtures A and B and a comparison of UV intensity at 280 nm of samples incubated for
21 days
Incubation
mixture

Particle
diameter
(nm)

Mass of
gold/mL
(g/mL)

Particle
number/mL

Total particle
surface area/mL
(nm2/mL)

UV absorbance
at 280 nm (AU)

%
glycation

A

2 nm

1.21×10-5

1.5×1014

18.8×1014

0.180±0.008

46.9%

5 nm

6.32×10

-5

5.0×10

39.3×10

14

0.151±0.005

39.3%

20 nm

5.66×10-5

7.0×1011

8.79×1014

0.269±0.010

70.1%

2 nm

5.65×10-6

7.0×1013

8.79×1014

0.259±0.006

67.4%

5 nm

1.26×10-5

1.0×1013

8.79×1014

0.263±0.006

68.5%

20 nm

5.66×10-5

7.0×1011

8.79×1014

0.269±0.010

70.1%

Control solution

Not applicable

Not applicable

Not applicable

Not applicable

0.384±0.011

100%

BSA blank

Not applicable

Not applicable

Not applicable

Not applicable

0.004±0.000

1.04%

†

B

13

Notes: †This solution had the highest GNP total surface are; denotes that the highest total surface area occurred in mixtures of A that contained 5 nm diameter GNPs
(r=2.5 nm) and colloidal concentrations (C) of particles/mL. The number 15.7×1015 nm2/mL was derived by using the formula 4πr2×C to represent GNPs’ total surface area.
All colloidal suspensions labeled B had a total surface area of 3.52×1015 nm2/mL. Percent glycation was determined on the basis of the UV reading of each sample relative to
that of the control solution set at 100%.
Abbreviations: UV, ultraviolet; BSA, bovine serum albumin; GNP, gold nanoparticles; r, radius.

were adjusted to contain BSA and D-ribose with final concentrations of 35 mg/mL and 20 mM, respectively.

Analysis of samples
Unless otherwise indicated, all reaction mixtures including
the control and blank solutions were prepared in triplicate
and incubated under sterile conditions at 37°C in a shaking
water bath for 21 days. Aliquots were drawn from the reaction
mixture at 0, 3, 7, 14 and 21 days of incubation. Samples were
then stored at -20°C until analysis. Analysis of the mixtures
was performed on samples that were thawed, centrifuged,
and purified by C4 ZipTip pipettes, EMD Millipore Co.
(Billerica, MA, USA).
A period of 21 days of incubation was selected for this
study because preliminary experiments had demonstrated
the formation of AGEs of BSA with D-ribose using the
conditions described.

Detection of glycated products
by UV–Vis spectrometry
UV–Vis experiments were performed with an UltroSpec
2100 instrument (Biochrom Ltd, Cambridge, UK) according to the method of Dutta and Seneviratne.31,32 Briefly, the
analysis was carried out at wavelengths ranging from 250
to 400 nm in a thermostatically controlled cuvette holder set
at 25°C±1°C. Prior to analysis, each specimen was diluted
50-fold to yield a UV absorption reading of less than 1.

Circular dichroism experiments
Circular dichroism (CD) analysis was performed with a
Jasco J-720 spectropolarimeter (Tokyo, Japan) using quartz

International Journal of Nanomedicine 2014:9

cuvettes with 1 mm path length. Interpretation of results
was performed by the Jasco’s Spectra Manager software.
Prior to spectral acquisition, the concentration of BSA in
each sample was adjusted to 0.5 mg/mL in 0.1 M phosphate
buffer, pH 7.2. CD spectral signatures for each sample were
obtained in the far ultraviolet region (190–250 nm) by taking
the average of ten consecutive scans. The bandwidth in each
case was adjusted to 1 nm.

High performance liquid chromatography
experiments
Each HPLC run was performed in triplicate using a Hewlett
Packard 1050 system (Waldbronn, Germany) that included
a low-pressure gradient pump, a four-channel degasser, a
sequential auto sampler and a programmable fluorescence
detector (HP 1046A). The HPLC equipment was operated
with the ChemStation software from Agilent Technologies
(Santa Clara, CA, USA). All AGE species were separated
on a Shodex (New York, NY, USA) RSpak C18 reverse phase
HPLC column (5 μm×4.6 mm×150 mm) with a 415 Å pore
size. Mobile phase A consisted of 0.1% trifluoroacetic acid
(TFA) and 1% acetonitrile in water. Mobile phase B included
0.1% TFA and 95% acetonitrile in water. A linear gradient
from 20% to 60% of mobile phase B was applied at a constant flow rate of 1.0 mL/min over 25 minutes. Fluorescence
measurements for monitoring glycated products were performed at excitation and emission wavelengths of 340 nm
and 420 nm, respectively. The above excitation and emission
values allowed optimal detection of AGEs. Prior to analysis,
all solvents were degassed and sonicated for 15 minutes and
all samples were filtered by a 0.22 μm membrane.
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Matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF)
mass spectrometry
Unless otherwise indicated, each sample destined for mass
spectrometric analysis was purified with a C4 ZipTip. Mass
spectrometric readings were performed on incubation mixtures (0.6 μL) spotted onto stainless steel sample plates.
Analysis of m/z ratios was performed on a Bruker Autoflex
MALDI–TOF spectrometer (Bruker Daltonics, Billerica,
MA, USA) in linear TOF mode with a 550 ns delay. All spectra represented the sum of 500 single laser shots randomized
over ten positions localized on the same spot (500/50). Mass
spectrometric data was evaluated with Bruker’s (Billerica,
MA, USA) FlexAnalysis and ClinProTools software. For
spotting purposes, protein samples were mixed in a 50%
aqueous acetonitrile solution (0.6 μL) saturated with sinapinic acid and containing 0.05% TFA.

Analysis of data by UV, CD, HPLC,
and MALDI-TOF
All UV, CD, HPLC, and MALDI-TOF experiments were
performed in triplicate and compared with their respective
control solution.

Results
UV–Vis spectroscopy studies showed that there were increases
in the UV absorption of all incubation mixtures that contained
BSA and D-ribose regardless of whether GNPs were included
in the reaction mixtures. Blank solutions containing BSA
alone or D-ribose alone yielded no increases in UV readings. Figures 1A and B show UV–Vis absorption profiles for
each reaction mixture at wavelengths ranging from 250 nm
to 390 nm. All samples yielded a prominent UV absorption

B

0.5

Control solution
20 nm GNP TS=8.79×1014 nm2/mL
2 nm GNP TS=18.8×1014 nm2/mL
5 nm GNP TS=39.3×1014 nm2/mL

0.4
0.3
0.2
0.1
0
250

270

290

310

330

350

Wavelength (nm)

370

390

UV absorbance (AU)

UV absorbance (AU)

A

at around 280 nm, which was attributed to the formation of
AGEs and their aromatic ring structures.33
Figure 2A and B display the time course UV absorption
profiles of all colloidal suspensions. The UV profiles show
three important findings: 1) that UV intensities increased over
time, 2) that UV absorption readings were highest in samples
that contained no GNPs but only BSA and D-ribose, and 3)
that the extent inhibition of glycation was relatable to the
colloidal suspension’s total surface area. The increase in UV
absorption from day 0 to day 21 was not surprising as previous studies in our lab and those of others have demonstrated
that glycation is a time-dependent process.13–15,21,22
Table 1 shows the percent glycation of BSA with GNPs
of similar and variable total surface areas relative to controls that contained no GNPs and whose glycation levels
were set at 100%. The data demonstrates that glycation
was most inhibited in colloidal suspensions that had the
highest total surface area (% glycation =39.3%) and were
least inhibited in those whose total surface area was lowest
(% glycation =70.1%). Additional results showed that so long
as the total surface areas were set the same, glycation levels
remained similar in all GNP treated incubation mixtures (see
Table 1, Figures 1B and 2B).
To evaluate the effect of the colloidal suspensions on
the conformational change of glycated BSA, CD scans were
performed at the far UV region31,34 on reaction mixtures
containing 1) the protein and D-ribose incubated with GNPs,
2) the protein and D-ribose incubated without GNPs (control
solution), and 3) on solutions containing BSA alone or BSA
with GNPs (blank solutions). Figure 3A and B show the
respective CD spectral profiles of mixtures A and B after
21 days of incubation at 37°C. As expected, native BSA alone
yielded a CD spectrum with well-defined α-helical features

0.5

Control solution
20 nm GNP TS=8.79×1014 nm2/mL

0.4

5 nm GNP TS=8.79×1014 nm2/mL
2 nm GNP TS=8.79×1014 nm2/mL

0.3
0.2
0.1
0
250

270

290

310

330

350

370

390

Wavelength (nm)

Figure 1 UV absorbance spectral profiles of incubation mixtures containing 35 mg/mL BSA and 20 mM D-ribose incubated with GNPs of different sizes (2 nm, 5 nm, and
20 nm) at 37°C for 21 days.
Notes: (A) All incubation mixtures had GNPs of varied total surface area. (B) All incubation mixtures had colloidal suspensions of the same total surface area. In both A and
B, the control solutions included BSA (35 mg/mL) with D-ribose (20 mM) only. Spectral readings ranged from 250 nm to 400 nm and glycation products absorbed maximally
at around 280 nm. Repeat experiments yielded similar UV absorption profiles for each of the incubation mixtures.
Abbreviations: UV, ultraviolet; BSA, bovine serum albumin; GNP, gold nanoparticles; TS, total surface area.
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B

Control solution
20 nm GNP TS=8.79×1014 nm2/mL
2 nm GNP TS=18.8×1014 nm2/mL
5 nm GNP TS=39.3×1014 nm2/mL
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0.4
0.35
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0.2
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0.1
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0

0

5
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UV absorbance at 278 nm (AU)

UV absorbance at 278 nm (AU)

A

Control solution
20 nm GNP TS=8.79×1014 nm2/mL
5 nm GNP TS=8.79×1014 nm2/mL
2 nm GNP TS=8.79×1014 nm2/mL

0.45
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0

0

5

10

15

20

Incubation period (day)

Incubation period (day)

Figure 2 UV absorbance time course profiles of reaction mixtures containing 35 mg/mL BSA and 20 mM D-ribose with GNPs of different sizes (2 nm, 5 nm, and 20 nm) incubated
at 37°C. (A) Incubation mixtures had colloidal suspensions of varied total surface area. (B) Incubation mixtures had GNPs of the same total surface area.
Notes: Aliquots (1 mL) from each sample were collected at different intervals (0, 3, 7, 14, and 21 days) and their UV intensities were measured in quartz cuvettes at 280 nm.
All data points represent the average of triplicate measurements with the bars at each point representing the respective standard deviation.
Abbreviations: UV, ultraviolet; BSA, bovine serum albumin; GNP, gold nanoparticles; TS, total surface area.

showing two prominent dips, one at 208 nm and the other
at 222 nm.34 The CD spectral profiles of mixtures containing BSA with D-ribose alone displayed similar features as
that of BSA, but with less pronounced dips at 208 nm and
222 nm. This result was not surprising since some loss in the
α-helical structure of the protein was expected to occur due
to nonenzymatic modification of BSA by D-ribose.14,34
The CD spectra in Figure 3A again demonstrated that
GNPs had an inhibitory effect on glycation and this inhibitory effect was modulated by the colloidal suspensions’ total
surface areas. In the presence of colloidal suspensions, the
secondary structure of the protein was most stabilized with
GNPs exhibiting the highest surface area and least stabilized
when GNPs of lowest total surface area were added. In

A

120

Control solution
20 nm GNP TS=8.79×1014 nm2/mL
2 nm GNP TS=18.8×1014 nm2/mL

80

5 nm GNP TS=39.3×1014 nm2/mL

Figure 3B, the most striking finding was the observation
that in incubation mixtures that had GNPs of the same total
surface area, CD spectral profiles were relatively similar. This
result, once again, suggested that so long as the total surface
areas of the GNPs were maintained similar, the inhibition of
BSA’s glycation remained the same. To quantify the extent
of BSA’s glycation in the presence and absence of GNPs,
we next focused on the analysis of the incubations mixtures
by HPLC.
Figure 4 displays the HPLC elution profiles of the control
incubation mixture and the colloidal suspensions in the A
labeled incubations. Peak 1 and peak 2 in each of the profiles
represent the fluorescent AGE products of BSA detectable at
excitation and emission wavelengths of 360 nm and 420 nm,

B

120

Control solution
20 nm GNP TS=8.79×1014 nm2/mL
5 nm GNP TS=8.79×1014 nm2/mL
2 nm GNP TS=8.79×1014 nm2/mL
Natural BSA
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40

0
200

210

220

230

250

40

0
200

210

220

230

240

250

–40

–40

–80

240

CD (mdeg)

CD (mdeg)

Natural BSA

Wavelength (nm)

–80

Wavelength (nm)

Figure 3 CD spectral profiles of respective reaction mixtures containing 35 mg/mL BSA and 20 mM D-ribose with GNPs of different sizes (2 nm, 5 nm, and 20 nm) after
21 days of incubation. (A) Incubation mixtures had colloidal suspensions of varied total surface area. (B) Incubation mixtures had GNPs of the same total surface area.
Notes: Included in the graphs are also the blank and the control solutions with the former containing BSA alone, and the latter containing BSA and D-ribose only. Repeat
experiments confirmed the reproducibility of the CD spectral profiles for each of the incubation mixtures.
Abbreviations: CD, Circular dichroism; BSA, bovine serum albumin; GNP, gold nanoparticles; TS, total surface area.
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35
Peak 2, Rt =15.87 minutes
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2 nm GNP TS=18.8×1014 nm2/mL
25
5 nm GNP TS=39.3×1014 nm2/mL
20
20 nm GNP TS=8.79×1014 nm2/mL

15
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5
0

Control solution

0

5

10

15

20

25

Retention time (minutes)
Figure 4 HPLC elution profiles of fluorescent AGE products in control solution and
in the reaction mixtures containing GNPs after 21 days of incubation at 37°C.
Notes: All reaction mixtures except for the control solution contained BSA
(35 mg/mL), D-ribose (20 mM), and GNPs of various total surface area. Control
solution contained BSA (35 mg/mL) with D-ribose (20 mM) only. Repeat experiments
confirmed the reproducibility of the HPLC elution profiles for each of the incubation
mixtures with AGE products appearing each time at retention times of 2.25 and
15.87 minutes. Under equivalent elution conditions, the blank solution containing
BSA alone yielded no fluorescence absorbing AGE peaks demonstrating that for
glycation to occur both protein and sugar were required (data not shown).
Abbreviations: HPLC, high performance liquid chromatography; AGE, advanced
glycation end products; BSA, bovine serum albumin; GNP, gold nanoparticles; TS,
total surface area.

respectively.33,35 Repeat HPLC analysis showed that these
peaks occurred routinely in all mixtures designated A and B.
Peak 1 had a retention time of 2.25 minutes and peak 2 had
a retention time of 15.87 min. HPLC elution profile of the
blank solution containing BSA alone yielded no fluorescence
peaks.
Table 2 shows the integrated areas under peak 1 and
peak 2 for every incubation mixture. Analysis of the data
demonstrates that glycation products were, once again,
most pronounced in the controls that contained only BSA
and D-ribose. HPLC elution profile of the control solution

yielded two AGEs peaks with a total peak area of 646.81.
In contrast, the formation of AGEs was less pronounced in
mixtures treated with colloidal suspensions. In each case
where colloidal suspensions were included, the amount of
glycated products were found to be relatable to the GNP’s
total surface area. Suspensions that had particles of the highest surface area yielded the lowest levels of glycation (total
AGE peak area =358.45), whereas those with the lowest
surface area exhibited the highest levels of AGE products
(total AGE peak area =480.1). Next, focus was placed on
MALDI-TOF mass spectrometric studies to compare the
mass shift in nonglycated BSA versus BSA in the colloidal
suspensions labeled A and B.
Figure 5 shows the MALDI-TOF mass spectral profiles
of BSA in 1) the blank solution containing BSA alone, 2) the
control solution containing BSA and D-ribose, and 3) the
suspensions designated as the A mixtures. The increase in
the mass of BSA after its glycation by D-ribose was due to
the condensation of the sugar molecules with the protein
during the glycation process.36
Table 3 summarizes the shift in the m/z values and the
number of D-ribose adducts on BSA in mixtures A and B
by a MALDI-TOF method described previously.36 Analysis
of the data confirmed the HPLC results and shows that the
most pronounced shifts in the m/z of the BSA peak occurred
in the control solution that contained only BSA and D-ribose.
Native BSA exhibited an m/z peak of 33,090 whereas that
of the control yielded an m/z=39,290. This difference in the
m/z values represented the condensation of 83 sugar residues
to the protein (see Table 3). In the case of the colloidal mixtures, the changes in the m/z values were less pronounced
indicating the inhibitory effects of GNPs on the glycation of
BSA by D-ribose. The MALDI-TOF data also shows that the
GNP mixture with the highest surface area yielded the lowest
glycation, generating a protein peak with an m/z =36,980.

Table 2 The physical characteristics of the GNP colloidal suspensions and the AGE analysis of incubation mixtures labeled A and B
by HPLC
Incubation mixture

A

2 nm
5 nm
20 nm
2 nm
5 nm
20 nm

B

Control solution
BSA blank

Total particle
surface area/mL
(nm2/mL)

AGE peak areas
Peak 1
Rt 2.25 min

Peak 2
Rt 15.87 min

Total AGE peak
(Peak 1+2)

18.8×1014
39.3×1014
8.79×1014
8.79×1014
8.79×1014
8.79×1014
Not applicable
Not applicable

22.01
12.35
44.23
43.60
46.26
44.23
144.48
0.00

374.43
346.10
435.87
423.72
432.59
435.7
502.33
0.00

396.44
358.45
480.1
467.32
478.85
480.93
646.81
0

Abbreviations: GNP, gold nanoparticles; HPLC, high performance liquid chromatography; AGE, advanced glycation end products; BSA, bovine serum albumin.
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Table 3 The physical characteristics of the GNP colloidal and the MALDI-TOF analysis of m/z value in each of the samples labeled
A and B
Incubation mixture

Total particle
surface area/mL
(nm2/mL)

Peak m/z
value (z=2)

Shifted m/z value
compared to blank
solution (z=2)

Number
of D-ribose
adducts

A

18.8×1014
39.3×1014
8.79×1014
8.79×1014
8.79×1014
8.79×1014
Not applicable
Not applicable

37,170
36,980
37,790
37,770
37,710
37,790
39,290
33,090

4080
3890
4700
4680
4620
4700
6200
0

54
52
63
62
62
63
83
0

2 nm
5 nm
20 nm
2 nm
5 nm
20 nm

B

Control solution
BSA blank

Abbreviations: GNP, gold nanoparticles; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; BSA, bovine serum albumin.

6,000

TS=18.8×1014 nm2/mL
Peak m/z: 37,170

4,000
3,000
2,000

2,000
1,500
1,000

1,000

500
32,000 34,000 36,000 38,000 40,000 42,000 44,000 46,000

32,000 34,000 36,000 38,000 40,000 42,000 44,000 46,000

m/z

20 nm GNP
TS=8.79×1014 nm2/mL
Peak m/z: 37,790

4,000

3,000

2,000

m/z

5,000

Intensity (au)

5,000

Intensity (au)

5 nm GNP
TS=39.3×1014 nm2/mL
Peak m/z: 36,980

2,500

Intensity (au)

5,000

Intensity (au)

3,000

2 nm GNP

Control solution
Peak m/z: 39,290

4,000

3,000

2,000

1,000
32,000

34,000

36,000 38,000

40,000 42,000

44,000

46,000

32,000 34,000 36,000 38,000 40,000 42,000 44,000 46,000

m/z

m/z

Blank solution
Peak m/z: 33,090

Intensity (au)

1,500

1,000

500

32,000 34,000 36,000 38,000 40,000 42,000 44,000 46,000

m/z
Figure 5 MALDI-TOF mass spectral profiles of incubation mixtures containing GNPs, and of the control and blank solutions.
Notes: Each reaction mixture contained BSA (35 mg/mL) and D-ribose (20 mM) in the presence of a GNP suspension of specific size ranging from 2 nm to 20 nm. Control
solution had no GNPs but contained BSA (35 mg/mL) and D-ribose (20 mM) only. Blank solution contained no GNPs and no D-ribose but contained BSA (35 mg/mL) alone.
Repeat experiments confirmed the reproducibility of the MALDI-TOF mass spectral profiles for every incubation mixture. Each of the peaks in the above MALDI-TOF
profiles represents doubly charged BSA (z=2).
Abbreviations: MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; GNP, gold nanoparticles; BSA, bovine serum albumin.
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Relative to native BSA, this represented the condensation of
52 D-ribose molecules to the protein. In contrast, the GNP
suspension with the lowest surface area yielded a BSA peak
with an m/z =37,790 which represented the condensation of
63 D-ribose molecules to the protein. Confirming the HPLC
results was also the observation that in colloidal suspensions
that had the same total surface areas, the number of D-ribose
addicts in each solution was similar.

Discussion
Previous studies have demonstrated that proteins can
spontaneously conjugate with gold atoms on nanoparticles to yield homogeneous suspensions.37,38 In the case
of human and bovine albumin, this conjugation has been
proposed to occur through the proteins’ cysteine and lysine
residues,38,39 with the lysine residues also serving as the
major sites of glycation.40 Although the mechanism for the
conjugation of these amino acids to GNPs remains unclear,
to date, two mechanisms, one for cysteine 39 and one for
lysine,38,41 have been proposed. The interaction between
cysteine residues and GNPs has been speculated to ensue
through ligand exchange reactions, whereas those with
lysine are suggested to depend on electrostatic forces.38,39,41
The electrostatic forces between lysine and GNPs are
suggested to occur from ionic bridges formed between
the positively charged lysine residues on the protein and
the negatively charged citrate on GNPs, which generate
a carboxylate-ammonium type of salt.37–39 The combined
interactions of cysteine and lysine residues are believed
to contribute to the GNPs stability and prevent the GNPs
from precipitating out of solution.37,38 In the case of lysine,
its binding with GNPs is also suggested to mask its positive charges, preventing the protein from participating in
glycation reactions.9,10
In summary, our results demonstrate that the addition of
GNPs to BSA and D-ribose reduced the formation of AGEs
and appeared to inhibit the glycation process. Particle size
and particle concentration allowed variations in the total
surface area of the colloidal suspensions influencing the
extent modification of BSA with D-ribose. For example,
the observation was made that colloidal suspensions of
highest total surface area yielded the lowest levels of glycation, whereas those with the lowest total surface area least
inhibited the formation of AGEs. Combined with these
observations was also the finding that colloidal suspensions of the same total surface areas caused similar levels
of glycation in incubation mixtures containing BSA and
D-ribose with GNPs.
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The correction between total surface area and the extent
of glycation inhibition by GNPs is speculated to be related
to the amount of binding sites on the surface of GNPs. As
the GNPs in this study were coated with citrate, and as the
binding of lysine to GNPs has been reported to occur through
the formation of salt bridges,38,39 one would anticipate that
GNPs with higher total surface area provided more negatively
charged sites for the binding of BSA’s positively charged
lysine residues. Henceforth, with lysine residues serving as
the major glycation sites for the protein, this latter phenomenon may have contributed to the variation in the levels of
AGE as they relate to GNP’s total surface area.
Considering that the in vivo formation of AGEs plays a
significant role in the pathophysiology of diabetes, there has
been an ongoing effort to seek agents that inhibit the glycation process.42–44 As GNPs can be used in vivo and can be
readily prepared, a deeper understanding of their antiglycation potential may lead to novel therapeutic approaches for
treating diseases whose complications relate to the formation
of AGEs.
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